Leptomeningeal metastasis
Conditions
Interventions
group 1:???????EGFR-TKIs ???????EGFR-TKIs 16/2000 Nimotuzumab combined with EGFR-TKIs
group2 :EGFR-TKIs alone
Sponsors
The Second Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with clear diagnosis of meningeal metastasis of lung cancer, including cytological diagnosis of cerebrospinal fluid and neuroimaging diagnosis; 2. Patients with a clear history of lung cancer: including histopathological diagnosis, or cell pathology combined with imaging diagnosis; 3. Patients aged 18-75 years old; 4. Subjects without severe abnormal liver and kidney function; blood routine examination showed that WBC was not less than 4.0 x 1012 and platelet was not less than 100 x 10^9; 5. Patients with no previous history of serious nervous system diseases; 6. Subjects without severe heterogenous state.
Exclusion criteria
Exclusion criteria: 1. Patients receiving other targeted drugs in addition to EGFR-TKI within 2 months, such as recombinant human endostatin, crizotinib, trastuzumab, etc.; 2. Subjects with ECoG score > 2 and neurological failure, including severe encephalopathy, imaging examination showed 3-4 degrees of white matter lesions, moderate or above coma, GCS score less than 9; 3. Patients with extensive and fatal systemic tumor progression and lack of effective treatment; 4. Patients with poor compliance or not suitable for the study due to other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the rate of PFS; | — |
Countries
China
Contacts
Public ContactBu Hui
The Second Hospital of Hebei Medical University
Outcome results
None listed